Derazantinib is a multi-kinase inhibitor under investigation as an active pharmaceutical ingredient. It is being studied in clinical trials for conditions involving FGFR2 gene fusions.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing Derazantinib?
Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.
Tenapanor hydrochloride
pharmaceutical raw material
Rivastigmine
pharmaceutical raw material
Tenapanor
pharmaceutical raw material
Prulifloxacin
pharmaceutical raw material
The international HS code for Derazantinib (CAS 1234356-69-4) is 2933.59.
2933.59
2933 59 95
Classification per the EU customs inventory ECICS (2026-07 snapshot, HS 2022). National tariff lines and product form can affect the final classification.
(6R)-6-(2-fluorophenyl)-N-[3-[2-(2-methoxyethylamino)ethyl]phenyl]-5,6-dihydrobenzo[h]quinazolin-2-amine
KPJDVVCDVBFRMU-AREMUKBSSA-N
COCCNCCC1=CC(=CC=C1)NC2=NC=C3C[C@H](C4=CC=CC=C4C3=N2)C5=CC=CC=C5F
Sourcing Derazantinib?
Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.